Search Results
Your search for world matches 4350 pages
Showing 2101 - 2150Tumor Size and Grade Matter, and Ovarian Ablation by Chemotherapy May Explain Subgroup Anomaly in TAILORx
At the 2019 ASCO Annual Meeting, and simultaneously in The New England Journal of Medicine, we heard the third paper reporting results from TAILORx.1,2 The first, in 2015,3 indicated that women with node-negative breast cancers with Oncotype DX recurrence scores less than 11 did extremely well...
Novel Treatments Under Study in Renal Cell Carcinoma and Prostate Cancer
There were numerous notable presentations at the 2019 Genitourinary Cancers Symposium, many of which were covered in The ASCO Post over the past few months. To add to our continued coverage of this meeting, here are some highlights from studies focusing on novel therapeutics in renal cell carcinoma ...
Virtual Reality May Improve Pain, Vision, Functioning in Patients With Cancer
Virtual reality can be used to improve functioning in patients with cancer, according to David Rhew, MD, Chief Medical Officer, Vice President and General Manager of Enterprise Healthcare, Samsung Electronics America. Research has shown that this technology can decrease pain and improve vision, as...
Optimal First-Line Therapy for Stage IV Non–Small Cell Lung Cancer: Immunotherapy Alone or With Chemotherapy?
Recent studies in non–small cell lung cancer (NSCLC) have shown benefit for combining checkpoint inhibitors with chemotherapy. Should combinations, therefore, be the first choice for treating patients with newly diagnosed stage IV disease? Two lung cancer experts debated this point at the 2019...
All Oncologists Are Geriatric Oncologists...They Just Don’t Know It Yet
You don’t have to be a geriatrician to properly evaluate and manage older patients with cancer. The wave of older patients with cancer predicted over 30 years ago is now fully upon us. The oncology community finds itself ill-prepared to manage the increased number of older patients. It is not just...
What Causes Liver Injury During Treatment With Pembrolizumab
Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a game changer...
Cancer Research Institute Names New ‘STARs’ of Cancer Immunotherapy Research
The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of immunotherapies for all types of cancer, recently unveiled the inaugural cohort of scientists chosen for the CRI Lloyd J. Old STAR Program (Scientists Taking Risks). Each “STAR” will receive...
A Clinical Trial Was the Right Choice for Me
I found my cancer quite accidentally. In March 2018, as I was taking a shower, my hand casually brushed against my right mastoid bone, and I noticed the area sounded hollow. Around the same time, I realized I had developed a sense of fullness in that ear as well. I had been feeling tired, but that...
MORE Health Collaborates With Memorial Sloan Kettering
MORE Health, a global health-care company, recently announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) that gives patients from around the world access to the physicians and services of MSK through MORE Health’s Physician Collaboration Platform. MORE Health,...
V. Craig Jordan, CMG, OBE, PhD, DSc, Honored for Accomplishments in Women’s Health
The Companion of the Most Distinguished order of St. Michael and St. George (CMG) is generally reserved for ambassadors and leaders of the United Kingdom’s defense and security services. Only 1, 750 appointees are permitted. This year, the Head of M16, the Secret Intelligence Service, was in the...
Oral Antibiotics and Risk of Colon or Rectal Cancer
In an extensive data mining analysis of British medical records, researchers found that taking even a single course of antibiotics might boost—albeit slightly—the risk of developing colon cancer, but not rectal cancer, a decade later. The findings, reported by Zhang et al in Gut,...
What Causes Liver Injury During Treatment With Pembrolizumab
Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a game changer...
An Early Decision to Become an Oncologist
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. For this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Gilberto de Lima...
Surgical Resection Among Patients Receiving Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer
In an Italian prospective cohort study reported in JAMA Surgery, Maggino et al found that among patients receiving primary chemotherapy for newly diagnosed pancreatic ductal adenocarcinoma, conversion to surgical resection was achieved in 24% of those with borderline resectable disease and 9% of...
FDA OCE and Syapse Announce Research Collaboration Focused on Regulatory Use of Real-World Evidence
Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multiyear research collaboration agreement focused on the use of real-world evidence to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to...
Germline RABL3 Mutation May Increase Risk of Pancreatic Cancer Development
Scientists who studied a highly cancer-prone single family have identified a rare, inherited gene mutation that may raise the lifetime risk of pancreatic and other cancers. Their findings were published by Nissim et al in Nature Genetics. The discovery of the previously unknown mutation could lead ...
WHO Releases Report on the Global Tobacco Epidemic
On July 26, 2019, the World Health Organization (WHO) issued a new report, “Global Tobacco Epidemic 2019,” to discuss national efforts being made to implement effective strategies from the WHO Framework Convention on Tobacco Control that have been proven to reduce the demand for tobacco....
The Opioid Overdose Crisis: Victims, Villains, and the Gray Area in Between
According to politicians and the media, such as award-winning journalist Beth Macy, we are in the midst of the worst drug crisis in American history. Sparked first by oxycodone and broadening into heroin and fentanyl, opioid addiction is indeed ravaging communities across the nation, largely in...
Erdafitinib for FGFR-Altered Advanced Urothelial Carcinoma
This week, we review a phase II trial of erdafitinib in urothelial carcinoma with an FGFR alteration. We also talk about a report from the World Health Organization on tobacco use worldwide. Then, we discuss two recent U.S. Food and Drug Administration approvals in prostate cancer and a rare joint...
Circulating Tumor DNA Analysis for Detection of Residual Disease in Breast Cancer
Researchers have developed a new method for tracking residual disease in patients with breast cancer that could one day help doctors better tailor treatments and prevent unnecessary surgeries for some people with the disease. Findings were published by McDonald et al in Science Translational...
First-Degree Familial Risk in Blood Cancer Development
New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with a hematologic malignancy themselves. A study by Sud et al published in Blood offers the first...
Highlights in Geriatric Hematology From the ASH Annual Meeting & Exposition
GUEST EDITOR Geriatrics for the Oncologist is guest edited by Stuart M. Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer Center, Commack, New York, and...
COTA Signs Research Collaboration Agreement With FDA
COTA, Inc, a precision medicine technology company, announced that it has signed a 2-year Research Collaboration Agreement with the U.S. Food and Drug Administration (FDA) Information Exchange and Data Transformation (INFORMED) Program, the Agency’s data science and technology incubator that...
Novel Therapeutics on the Horizon for Treating Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is a major clinical problem, and better therapies are needed for both its treatment and prevention. According to Charles Loprinzi, MD, a medical oncologist at the Mayo Clinic in Rochester, Minnesota, to devise better preventive and treatment approaches,...
Notable Presentations at ASCO 2019 Included Studies in Sarcoma, Lymphoma, Myeloma, and Breast and Kidney Cancers
The 2019 ASCO Annual Meeting featured a wealth of presentations on important topics. In addition to our regular news coverage of the meeting, we present below some highlights of other studies that add to our knowledge base for treatment of various cancers. Olaratumab in Soft-Tissue Sarcoma...
What Causes Liver Injury During Treatment With Pembrolizumab?
Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a...
How an Innovative AI-Based Smartphone Application Is Addressing Patients’ Palliative Care Needs
GUEST EDITOR Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD, FASCO. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development. During the 2019...
BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer
The three-drug combination of encorafenib (a BRAF inhibitor), binimetinib (a MEK inhibitor), and cetuximab (an EGFR inhibitor) significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to the results of the phase III BEACON CRC clinical trial....
What Causes Liver Injury During Treatment With Pembrolizumab?
Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a game changer...
Psychological Stress and Cancer-Specific Mortality in Patients With Cervical Cancer
Results from a large cohort study showed that psychological stress is associated with increased cancer-specific mortality among women with cervical cancer, independent of tumor characteristics and treatment modality. The findings support the integration of psychological screening and intervention...
WHO Releases Report on the Global Tobacco Epidemic
Many governments are making progress in the fight against tobacco, with 5 billion people today living in countries that have introduced smoking bans, warnings on packaging, and other effective tobacco control measures—four times more people than a decade ago. However, a new World Health...
Automated Breast Cancer Detection Assay Using Fine-Needle Aspiration May Aid Patients in Developing Countries
A new laboratory test developed to identify chemical changes to a group of cancer-related genes may be able to accurately detect which breast tumors are cancerous or benign. Such a test could result in a more timely diagnosis of breast cancer for women in developing countries with less access to...
Deep Natural Language Processing of Oncology Radiology Reports
Scientists have demonstrated that an artificial intelligence (AI) tool can perform as well as human reviewers—and much more rapidly—in extracting clinical information regarding changes in tumors from unstructured radiology reports for patients with lung cancer. These findings were...
Friends of Cancer Research Launches Next Phase in Real-World Evidence Initiative
FRIENDS OF CANCER RESEARCH (Friends) is launching the next phase of its Real-World Evidence pilot project after a broad stakeholder meeting in February 2019. At the meeting, the U.S. Food and Drug Administration (FDA) and various data partners expressed interest in continuing to address several...
Jason S. Lewis, PhD, Receives SNMMI Award for Outstanding Achievement in Basic Nuclear Medicine Science
Jason S. Lewis, PhD, has been named the 2019 recipient of the Paul C. Aebersold Award. Dr. Lewis is the Emily Tow Jackson Chair in Oncology and Vice Chair for Research and Chief Attending, Radiochemistry and Imaging Sciences Service, Department of Radiology at Memorial Sloan Kettering Cancer...
How the ASCO Breakthrough Global Summit Is Bringing Together Innovators to Transform Cancer Care
Earlier this year, ASCO announced plans for its first-ever international meeting, ASCO Breakthrough: A Global Summit for Oncology Innovators, which will be held October 11–13, 2019, in Bangkok, Thailand. The meeting is a joint effort by ASCO and the Thai Society of Clinical Oncology to bring...
No Man Is an Island: Reflections From an ASCO IDEA Recipient
IT WAS a chilly Chicago morning, and I was sitting at the lobby of my hotel when I saw a smiling gentleman cheerfully waving at me from his car. It was Lawrence H. Einhorn, MD, picking me up for our drive to Indiana. I was one of the recipients of the ASCO International Development and Education...
Activity of a MEK 1/2 Inhibitor in Select Pediatric Brain Cancers
In a phase II trial reported in The Lancet Oncology, Jason Fangusaro, MD, and colleagues found that the MEK1/2 inhibitor selumetinib was active in pediatric patients with recurrent, refractory, or progressive pilocytic astrocytoma with common BRAF aberrations and neurofibromatosis type 1...
Physicians and the Threat of Nuclear War
The Hippocratic Oath calls on physicians to “use treatment to help the sick according to my ability and judgment,” but not all versions of the oath call on us to prevent disease. Here we urge our colleagues to acknowledge that additional mandate and renew their commitment to preventing what could ...
The Unhealthy Health-Care System, and How to Fix It
BOOKMARK Title: An American Sickness: How Healthcare Became Big Business and How You Can Take It BackAuthor: Elisabeth Rosenthal, MDPublisher: Penguin PressPublication Date: April 2017Price: $27.95, hardcover; 416 pages The United States spends considerably more on health care than all other...
Emergency Medicine Doctor Reflects on 5 Decades of Career Experiences
BOOKMARK Title: Patient Care: Death and Life in the Emergency RoomAuthor: Paul Seward, MDPublisher: CatapultPublication Date: July 2018Price: $22.95, hardcover, 240 page The history of emergency medicine residency training is interlaced with the impetus for specialty status in emergency medicine,...
A Compassionate Family Doctor Sparked an Interest in Medicine for Lori Pierce, MD, FASTRO, FASCO
GUEST EDITOR Jame Abraham, MD, FACP Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. For this installment of the Living a Full Life series of articles, guest editor Jame Abraham, MD,...
Artificial Intelligence to Guide Management of Pancreatic Cysts
In a proof-of-concept study, an international scientific team has shown that a laboratory test using artificial intelligence tools has the potential to more accurately sort out which people with pancreatic cysts will eventually develop pancreatic cancers. Their findings were published by Springer...
ESMO World GI: Findings From the BEACON CRC Trial and More
We discuss two studies on colorectal cancer that were presented at the ESMO World Congress on Gastrointestinal Cancer. We also talk about a recently published study on the prevalence of pain among cancer survivors in the U.S.
Friends of Cancer Research Launches Next Phase in Real-World Evidence Initiative
Friends of Cancer Research (Friends) is launching the next phase of its Real-World Evidence (RWE) pilot project after a broad stakeholder meeting in February 2019. At the meeting, the U.S. Food and Drug Administration (FDA) and various data partners expressed interest in...
Henry T. Lynch, MD, Trailblazer in Hereditary Cancers, Dies at 91
Henry T. Lynch, MD, widely known as “the father of cancer genetics,” had an early life that could have been lifted from the pages of a Louis L’Amour novel. He dropped out of high school and using a falsified birth certificate joined the U.S. Navy at 16 years old, serving as a gunner on a marine...
Chaga Mushroom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, explore the current...
The Bomb
I sit paralyzed at my desk. Everyone else has left the clinic. I can hear the sound of the broom in the hall as the after-hours cleaning begins. No phones ring, no patients hurry to appointments, no chatter lingers in the air. The silence is oppressive, the air is heavy, and the distance from my...
Benefit Seen With Targeted Therapies in Elderly and Medically Complex Patients With Metastatic RCC
Many elderly and medically complex patients with metastatic renal cell carcinoma (RCC)—who are often underrepresented in clinical trials—saw overall survival benefits from treatment with targeted therapies, according to a study that analyzed 13 years of data on Medicare patients...
ESMO World GI 2019: BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer
The three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to results of the phase III BEACON CRC clinical trial. These findings were presented by Kopetz et al at the European...
